INNV · InnovAge Holding Corp.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INNV
this stock
InnovAge Holding Corp.
|
$1.46B | +107.1% | +11.8% | — | 0.6% |
|
HCA
HCA Healthcare, Inc.
|
$89.85B | -13.3% | +7.1% | 14.0 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.66B | -11.2% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.34B | +33.4% | +0.9% | 10.2 | 3.1% |
|
FMS
Fresenius Medical Care AG
|
$12.06B | -4.9% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INNV | -1.0% | -3.9% | +23.1% | -0.5% | +107.1% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -1.1% | -3.5% | +8.0% | -0.9% | +94.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.